prikaz prve stranice dokumenta Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients’ Pharmacogenetic Profile
Access restricted to all Croatian higher education institution's students and staff
Scientific paper - Review paper
Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients’ Pharmacogenetic Profile
Basic & Clinical Pharmacology & Toxicology, 123 (2018), 4; 509-518. https://doi.org/10.1111/bcpt.13035
Vrkić Kirhmajer, Majda; Macolić Šarinić, Viola; Šimičević, Livija; Ladić, Iva; Putarek, Krešimir; Banfić, Ljiljana; Božina, Nada

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Vrkić Kirhmajer, M., Macolić Šarinić, V., Šimičević, L., Ladić, I., Putarek, K., Banfić, Lj. & Božina, N. (2018). Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients’ Pharmacogenetic Profile. Basic & Clinical Pharmacology & Toxicology, 123. (4), 509-518. doi: 10.1111/bcpt.13035

Vrkić Kirhmajer, Majda, et al. "Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients’ Pharmacogenetic Profile." Basic & Clinical Pharmacology & Toxicology, vol. 123, no. 4, 2018, pp. 509-518. https://doi.org/10.1111/bcpt.13035

Vrkić Kirhmajer, Majda, Viola Macolić Šarinić, Livija Šimičević, Iva Ladić, Krešimir Putarek, Ljiljana Banfić and Nada Božina. "Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients’ Pharmacogenetic Profile." Basic & Clinical Pharmacology & Toxicology 123, no. 4 (2018): 509-518. https://doi.org/10.1111/bcpt.13035

Vrkić Kirhmajer, M., et al. (2018) 'Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients’ Pharmacogenetic Profile', Basic & Clinical Pharmacology & Toxicology, 123(4), pp. 509-518. doi: 10.1111/bcpt.13035

Vrkić Kirhmajer M, Macolić Šarinić V, Šimičević L, Ladić I, Putarek K, Banfić Lj, and sur.. Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients’ Pharmacogenetic Profile. Basic & Clinical Pharmacology & Toxicology [Internet]. 2018 [cited 2024 April 28];123(4):509-518. doi: 10.1111/bcpt.13035

M. Vrkić Kirhmajer, et al., "Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients’ Pharmacogenetic Profile", Basic & Clinical Pharmacology & Toxicology, vol. 123, no. 4, pp. 509-518, 2018. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:203793. [Accessed: 28 April 2024]

Metadata
Title (english)Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients’ Pharmacogenetic Profile
AuthorMajda Vrkić Kirhmajer
MBZ: 319133
AuthorViola Macolić Šarinić
MBZ: 188196
AuthorLivija Šimičević
MBZ: 384903
AuthorIva Ladić
AuthorKrešimir Putarek
MBZ: 238462
AuthorLjiljana Banfić
MBZ: 224315
AuthorNada Božina
MBZ: 91773
Author's institutionUniversity of Rijeka
Faculty of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Abstract (english)
Up to the beginning of 2018, a total of eight cases describing rare but clinically important drug interactions between rosuvastatin and ticagrelor which resulted in rhabdomyolysis have been noted in the Global World Health Organization (WHO) adverse drug reaction (ADR) database (VigiBase) as well as in available literature. There are several possible factors which could contribute to the onset of rhabdomyolysis: old age, initially excessive rosuvastatin dose, drug-drug interactions (DDI) on metabolic enzymes (CYPs and UGTs) and drug transporter levels (ABCB1, ABCG2, OATP1B1) and pharmacogenetic predisposition. We reviewed all available cases plus the case of an 87-year-old female Croatian/Caucasian patient who developed rhabdomyolysis following concomitant treatment with rosuvastatin and ticagrelor. The results of the pharmacogenetic analysis indicated that the patient was a carrier of inactivating alleles CYP2C9*1/*3, CYP3A4*1/*22, CYP3A5*3/*3, CYP2D6*1/*4, UGT1A1*28/*28, UGT2B7 -161C/T, ABCB1 3435C/T and ABCB1 1237C/T which could have added to the interactions not only between ticagrelor and rosuvastatin but also other concomitantly prescribed medicines, such as amiodarone and proton pump inhibitors. In this case report, the possible multifactorial causes for rhabdomyolysis following concomitant use of rosuvastatin and ticagrelor such as old age, polypharmacy, renal impairment, along with pharmacogenetics will be discussed
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleBasic & Clinical Pharmacology & Toxicology
Numberingvol. 123, no. 4, pp. 509-518
p-ISSN1742-7835
DOIhttps://doi.org/10.1111/bcpt.13035
URN:NBNurn:nbn:hr:184:203793
Publication2018
Document URLhttp://bib.irb.hr/1050352
Type of resourceText
Access conditionsRestricted access
Terms of useLicence In copyright icon
Created on2022-03-08 11:27:56